SILEXION THERAPEUTICS CORP (SLXN) Stock News
NASDAQ:SLXN - Nasdaq - Common Stock
SLXN Latest News and Analysis
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Top movers in Thursday's session
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials planned for 2026.
Gapping stocks in Thursday's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures
Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.
What's going on in today's pre-market session
Stay updated with the stocks that are on the move in Thursday's pre-market session.
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech...
Wednesday's after hours session: top gainers and losers
After hours stock analysis on 2025-01-15: top gainers and losers in today's session.
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
Significant new preclinical results demonstrate synergistic activity of SIL-204 with 5-fluorouracil and irinotecan as well as gemcitabine, reinforcing its...
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers...
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist...
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ...
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA...
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage,...
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024...